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ABSTRACT 
Objective: Chloramphenicol is poorly released from official eye ointment (EO) base. This study investigated alternative promising bases, enhanced 
drug release with surfactant and evaluated ocular tolerance of prototypes.  
Methods: Chloramphenicol eye ointment (1 %w/w) was prepared by levigation in five bases: EO, simple ointment (SO), hydrous wool fat (HW), 
hydrous sheabutter (HS), and neat sheabutter (NS). In-vitro drug release of these and EO and SO formulations containing graded concentrations 
(0.1–10.0 %w/v) of surfactant (polysorbate 80 or propylene glycol) were studied over 3 h by dialysis technique, and the release kinetics assessed. 
Water-absorption capacity (WAC) and melting temperature of the bases was determined for probable influence on drug release. Ocular tolerance of 
the formulations, bases and surfactants was evaluated by in vivo irritancy test on albino rabbits. 
Results: Total drug released from test formulations differed with base used: NS 12, HS 11, SO 7, HW 5, and EO 4 %. The Higuchi release kinetics was 
determined. HS and NS demonstrated highest release extent and rate; EO and HW exhibited poor release. WAC and softening temperature of bases showed 
some correlation with drug release propensity. Propylene glycol in EO and polysorbate 80 in SO formulations showed 3-fold and 2-fold enhanced drug 
release, respectively. All items for ocular toxicity test gave scores indicating practically no irritation, except neat HW that was mildly irritant.  
Conclusion: HS and NS proved best alternatives to EO. Propylene glycol (10 %) in the EO formulation was 3-fold drug-release enhanced. All 
prototype formulations were non-irritant to eye tissue. 
Keywords: Chloramphenicol, Ointment, Base, Surfactant, In-vitro Release, Ocular tolerance.  
 
INTRODUCTION 
Chloramphenicol is a broad-spectrum antibiotic often applied 
topically to conjunctiva for treatment of infections caused by 
susceptible microorganisms. It is the drug of choice in ocular 
infections because of its high transcorneal penetration and broad 
spectrum activity [1] and is administered as ophthalmic drops or 
ointment. The ointment offers an advantage of longer contact time 
over the solution drug form that suffers rapid and extensive pre-
corneal loss due to high lachrymal fluid turn over and drainage rate 
[2]. The potency of a topical medication is markedly influenced by its 
vehicle, e. g. an ointment base [3], and the corneal absorption of the 
administered drug may be enhanced by the presence of a surfactant 
[4]. Non-ionic surfactants (such as polysorbate 80) are found to be 
less toxic than anionic and cationic surfactants in predictive ocular 
irritancy studies [5] and are uniquely suited for topical ocular drug 
delivery through their potential ability to increase bioavailability by 
increasing drug solubility, prolonging pre-corneal retention, and 
enhancing permeability [6]. Polysorbate 80 (aqueous solution) has 
been used to produce nanoparticles for ocular delivery of 
hydrocortisone [7] and as a surfactant component of ocular 
indomethacin microemulsion [8]. Propylene glycol is a water-
diffusive liquid with surfactant property and useful as cosolvent and 
skin penetration enhancer for poorly soluble compounds in topical 
medicinal products [9]. When tested on rabbit eye, neat (undiluted) 
propylene glycol showed some measure of ocular irritation [10]. 
Also, occupational exposure to propylene glycol vapour has been 
reported to cause ocular irritation in human subjects [11]. However, 
dilutions of propylene glycol (at use concentrations) are generally 
non-toxic [12]. In vivo Draize eye test in rabbit [13] is the 
international standard assay for acute ocular toxicity [14].  
Eye ointment basis BP (EO) is a British Pharmacopoeial (standard) 
eye ointment vehicle generally recommended for use in eye 
ointment preparations [15]. But preliminary study in our laboratory 
suggested that chloramphenicol is poorly released from EO. Also, a 
vehicle for eye ointment medication is required to be non-irritant to 
the conjunctiva [15]. Yet, no information is found in literature on 
irritancy appraisal or ocular tolerance of EO, which should 
authenticate its suitability and general acceptability for ophthalmic 
use. Although the main components of EO (liquid and soft paraffin) 
are common pharmacopoeial ointment vehicle components which, 
in earlier ocular irritation studies, had been used as plain diluent or 
medium [16, 17], the lack of any literature data indicative of the 
ocular tolerance of EO or its components, even in later report on 
predictive eye irritation potentials of several substances in current 
use [18], is quite undesirable.  
Other established (pharmacopoeial) ointment bases were having 
similar components (paraffin, lanolin) to EO namely, simple 
ointment BP (SO) and hydrous wool fat BP (HW) are, however, for 
dermatologic use. These and sheabutter bases (hydrous sheabutter 
[HS] and neat sheabutter [NS]) are investigated in this study, being 
considered as prospectively useful alternative ophthalmic ointment 
vehicles for chloramphenicol. Sheabutter, extracted and purified 
from Vitellaria paradoxa C. F. Gaertn (Sapotaceae) nuts, has been 
earlier studied for use as a dermatologic ointment vehicle and its 
utility found comparable to that of established bases [19, 20]. 
However, for lack of satisfactory, unequivocal information on its 
safety for human use, sheabutter was listed by the European 
Commission 2006 among substances not exempted from 
registration [21].  
A valuable dermatologic vehicle, nonetheless, holds promise for 
advantageous ophthalmic application if it is innocuous on the eye tissue. 
Ocular tolerance testing of promising dermal ointment vehicles could 
lead to expansion of their utilities. Hence it was adjudged important to 
ascertain, by testing, the ocular toxicity potential of EO and of the 
propitious dermatologic bases: SO, HW, HS and NS as necessary premise 
for recommendation or proscription of their ophthalmic use. Therefore 
the objectives of this study were to determine ocular irritation potential 
of the bases and of chloramphenicol eye ointment prepared with each 
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base in the absence and presence of polysorbate 80 or propylene glycol 
as drug-delivery enhancement surfactant; and to evaluate drug release 
propensity of the formulations.  
MATERIALS AND METHODS 
Materials  
Chloramphenicol in powder, anhydrous (SIGMA); cellulose dialyzer 
tubing (SIGMA); propylene glycol (May and Baker, England); 
cetostearyl alcohol, lanolin anhydrous (British Drug Houses, 
England); polysorbate 80, hard paraffin, liquid paraffin, white soft 
paraffin (William Ransom & Sons. England); neat sheabutter, freshly 
processed from shea nuts (National Center for Agricultural 
Mechanization, NCAM, Ilorin Nigeria). 
Methods 
Preparation of bases for chloramphenicol eye ointment  
Five ointment bases (EO, SO, HW, HS, and NS; table 1) were 
prepared. The EO, SO, and HW compounded according to 
compendium guidelines [15], and HS produced from NS were 
prepared sterile. EO and SO were dry-heat sterilized (BP procedure) 
while HW, HS and NS were oven-melted (≤ 60 °C) and sterilized by 
membrane filtration aided by suction pump. Freshly sterilized HS 
and NS base samples having polymorphic property were kept 
(undisturbed) at the ambient temperature (28±2 °C) for 5 d before 
use, to allow full restoration and stability of their physical 
characteristics and semisolid consistency [22].  
 
Table 1: Composition of ointment bases 
 Name of base/Ingredient concentrations (%w/w) 
Ingredients Eye ointment basis BP Simple ointment BP Hydrous wool fat BP Hydrous sheabutter 
Soft paraffin 80 85 – – 
Wool fat 10 5 75 – 
Liquid paraffin 10 – – – 
Hard paraffin – 5 – – 
Cetostearyl alcohol – 5 – – 
Water (purified) – – 25 18 
Neat sheabutter – – – 82 
Key:–Ingredient not contained in base 
 
Determination of softening/melting point and water-
absorption capacity of ointment bases 
Softening and melting temperatures of the bland bases were 
determined using the method for suppository bases as described by 
Adebayo and Akala [23]. The temperature at which the base sample 
began to liquefy was defined as the softening point, while the 
temperature of complete liquefaction was the melting point. The 
mean and standard deviation (SD) of four determinations was 
recorded. The possible influence of water-absorption capacity 
(WAC) of ointment base on drug release propensity of the composite 
(medicated) ointment formulation was assessed. Mean WAC of each 
base was determined from quadruplicate tests at the ambient 
temperature, using the pharmacopoeial method described for 
hydrous wool fat [15].  
Preparation of medicated ointment 
Chloramphenicol eye ointment (1 %w/w) samples, 20 g each, were 
prepared at the ambient temperature with each of the five ointment 
bases by levigation method and aseptic processing, for subsequent 
eye irritation and drug release testing. The medicated ointment 
samples in EO and SO containing either propylene glycol or 
polysorbate 80 (surfactant) at graded concentrations (0.1, 0.5, 1.0, 
5.0 or 10.0 % w/v) were also prepared for drug-release 
enhancement testing. The requisite amounts of the drug (≤ 90 μm 
particle size) and surfactant were incorporated into each base, 
respectively. Each preparation was aseptically packaged in sterile 
disposable 2 or 5-ml capacity hypodermic syringes from which to be 
dispensed at the point of use, and kept for a minimum of 24 h at the 
ambient temperature before testing, to permit equilibration with the 
environment.  
In-vitro drug release studies 
The release rate of chloramphenicol from each medicated ointment 
sample was determined using an in-vitro dialysis technique 
described earlier [19]. The release compartment was a 4 g 
medicated ointment sample enclosed in 8 cm long cellulose dialyzer 
tube previously hydrated in water for 24 h at room temperature, 
suspended vertically on the rotary shaft of an Erweka dissolution 
apparatus (Heusenstamm Kr. Offenbach, Germany) and set to 
revolve at 50 rpm. The dissolution medium was a phosphate buffer 
solution (900 ml, pH 7.2) maintained at 37±0.5 °C, simulating 
lachrymal fluid pH [24]. Samples of the dissolution-medium (5 ml 
each) were withdrawn at specified time intervals for 180 min and 
assayed for chloramphenicol. The volume of dissolution medium 
was kept constant by replacing withdrawn volumes with equal 
amount of fresh medium maintained at the same temperature. The 
amount of drug in withdrawn samples was analyzed 
spectrophotometrically at 278 nm (JENWAY 6305, UK). A calibration 
graph was generated from a concentration range of the drug (0.5 to 
4.0 mg/ml) prepared in pH 7.2 phosphate buffer solution which 
showed a λmax of 1.239 UV absorbance at 278 nm wavelength, from 
which the amount of drug in solution at each sampling time was 
determined.  
In vivo study 
Animal ethics and experimental conditions 
The study was approved by the Health Research and Ethics 
Committee of Obafemi Awolowo University (OAU) Ile-Ife Nigeria 
(Ref. no. OAUTHC/CS/232/Vol. V/268), and executed according to 
the Test Guidelines no. 405 of the Organization for Economic 
Cooperation and Development (OECD) in adherence to the 
Association for Research in Vision and Ophthalmology (ARVO) 
Statement for the use of animals in ophthalmic and vision research. 
Healthy, New Zealand White albino rabbits (0.7–2.0 kg) of both 
sexes without pre-existing ocular irritation was selected for the 
study. The females were nulliparous and non-pregnant. The animals 
were nurtured in the animal house of the Faculty of Pharmacy, OAU 
Ile-Ife; housed in 56 × 56 × 46 cm well ventilated stainless steel 
suspended cages, and were provided with standard feed from the 
OAU Biological Gardens Unit, occasionally supplemented with herb 
(Tridax procumbens Linn), and water ad libitum. The animal room 
was maintained at temperature 26-30 °C, humidity 50-80 %, and 
light/dark cycle 12h/12h conditions. Prior to dose initiation, the 
rabbits were acclimatized to laboratory conditions for 21 d.  
Primary eye irritation test on rabbits 
The potential of each test item to cause irritation from a single 
ocular instillation in a group of 3 rabbits as experimental bio-model 
was assessed as recommended by the OECD, to determine the ocular 
tolerance profile. The test items were: 0.1 g of each ointment base 
and of the medicated ointment prepared in each base, and 100 µl of 
each surfactant solution (10 %w/v) in purified water. Three animals 
were used per test substance, which was instilled into the 
conjunctival sac of the right (test) eye of each rabbit by gently 
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pulling the lower lid away from the eyeball. The upper and lower 
lids were then gently held together for ~ 1 s to avoid loss of the test 
substance. The left eye of each animal remained untreated as 
control. Following treatment, ocular irritation was evaluated 
macroscopically using a high-intensity white light (Mag Lite) at 1, 
24, 48, and 72 h post-instillation.  
To minimize the number of animals used, any test animal showing no 
untoward response to applied treatment was reused once only, after a 
14-day rest/re-acclimatization period under the laboratory conditions. 
Twenty-four animals in all (10 males, 14 females) were used in the 
study. Individual eye irritation scores were recorded for each animal. 
Absence of corneal damage at 24 h was verified by fluorescein dye 
evaluation. Ocular lesions were scored according to the Scale for 
Scoring Ocular Lesions [25]. Any other observed lesions were noted in 
addition to observations of the cornea, iris and conjunctivae. The 
rabbits were also monitored at least once daily for signs of gross 
toxicity or behavioral changes during the test period. The average 
score for all 3 rabbits per group at each scoring point was calculated. 
For evaluation of the overall eye irritation scores, the time interval 
with the highest mean score (Maximum Mean Total Score, MMTS) for 
all rabbits in the group was used to classify the test substance in 
accordance with the scoring system of Kay and Calandra [26].  
Data analysis and statistics 
The extent of drug release was assessed from the total amount of drug 
present in the dissolution medium at the end of 180 min. The drug 
release kinetics applicable for the ointment samples was evaluated by 
analyzing with three mathematical models: zero-order kinetics (Q vs 
t), diffusion-controlled (or Higuchi) model (Q vs square-root of t), and 
first order kinetics (log[Qo–Q] vs t), where Q is the amount of drug 
released at time 't' and Qo is the initial amount of the drug. The model 
that consistently produced the highest correlation for the ointment 
preparations was used for assessment of drug release rates, and the 
slope obtained from linear regression analysis of the plot was 
determined as the drug release rate constant. The results expressed as 
mean±SE (standard error of the mean percent drug-released values of 
pooled data) were generated from triplicate determinations for each 
ointment formulation. The data were subjected to t tests, analysis of 
variance (ANOVA) and F-test to determine significance of mean drug-
released value differences.  
RESULTS 
Amounts and profile of chloramphenicol release from ointment 
bases 
The total amount of drug released from the chloramphenicol eye 
ointment formulations over 3 h testing period depended on the 
ointment base used. Over the period, the neat bases: NS released 12 %, 
HS 11 %, SO 7 %, HW 5 %, and EO 4 % of the drug (fig. 1). Also, while 
NS and HS gave gradual increase of the drug released over 3 h, the SO, 
HW and EO formulations exhibited a drug release peak and no further 
appreciable release beyond 60, 120 and 120 min, respectively.  
 
 
Fig. 1: Release profile of chloramphenicol (1 %w/w) eye 
ointment in different bases 
 
For determination of chloramphenicol release kinetics, consistent 
highest correlation of linear plots occurred when the amounts of 
drug released were plotted against the square root of time in 
accordance with the Higuchi kinetics. The correlation coefficient 
values obtained for most data of other kinetic models (zero and first 
order) were consistently lower (table 2), implying preponderance of 
the diffusion-controlled release mechanism for the drug. 
  
Table 2: Diffusion-controlled rates and correlation coefficients of chloramphenicol release mechanism profiles from ointment bases 
Ointment base Diffusion-controlled model First-order model 
correlation coefficient 
Zero-order model correlation coefficient 




Eye ointment basis 
BP 
0.07 0.88 0.88 0.88 
Simple ointment 
BP 
0.27 0.87 0.72 0.71 
Hydrous wool fat 
BP 
0.17 0.98 0.94 0.94 
Hydrous 
sheabutter 
0.34 0.98 0.94 0.94 
Neat sheabutter 0.28 0.94 0.93 0.92 
The chloramphenicol release rate constant values in the ointment bases ranked in the order: HS (0.34)>NS (0.28)>SO (0.27)>HW (0.17)>EO (0.07 
mg. min–½
 
). Thus, HS and NS demonstrated greater release potential for chloramphenicol than the pharmacopoeial bases (SO, HW and EO). When 
analyzed by ANOVA test, the release profile of chloramphenicol in the different ointment groups overall (i.e. by F test) differed significantly from 
one another (*P>0.05). However, t test comparisons showed that the release data of HS compared to NS formulations was not significantly different 
(*P<0.05).  
Effect of water-absorption capacity and softening temperature 
of base on drug release 
The WAC and softening of the bases apparently influenced their 
drug release propensity. With exception of HW, the bases (HS and 
NS) softening at ~37 °C and having relatively lower WAC values 
showed greater propensity for release of chloramphenicol than the 
bases (EO and SO) with higher softening temperature and WAC 
values (table 3). 37 °C is mammalian mean body temperature and 
the in-vitro test condition. Inclusion of a surfactant as a component 
of chloramphenicol eye ointment enhanced drug release from the EO 
and SO formulations selectively. Thus 10 % propylene glycol 
increased the amount of drug released in EO ointment from 4 % 
(over 3 h) in an absence of the surfactant (fig. 1) to 13.5 % (in ≥1.5 
h) when the surfactant was present (table 4).  
This represents more than three-fold enhancement of the drug 
release capacity of the base. Similarly, 10 % polysorbate 80 raised 
the drug released in SO ointment from 7 % (over 3 h) in absence of 
the surfactant to 18.9 % (in ≥2 h) when the surfactant was present, 
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which represents more than two-fold enhancement of the drug 
liberating potential of the base. However, the presence of propylene 
glycol and polysorbate 80 (surfactant) in SO and EO ointments, 
respectively, did not appreciably improve drug release (table 4). 
 
Table 3: Melting temperatures and water absorption capacity of ointment bases 
Ointment base Heat susceptibility Water-absorption capacity (ml/10 g)† 
Softening temperature ( °C) Melting temperature ( °C) 
Eye ointment basis BP 38.5±0.5 44.0±0.5 35.0 (0.4) 
Simple ointment BP 40.0±0.5 46.0±0.5 36.5 (0.4) 
Hydrous wool fat BP 37.0±1.0 43.0±2.0 20.5 (0.4) 
Hydrous sheabutter 37.5±2.0 42.5±1.5 10.5 (0.2) 
Neat sheabutter 37.0±0.5 38.5±0.5 19.0 (0.2) 
Key:-Mean values; with SD values in parenthesis 
 
Table 4: Effect of surfactant on release of chloramphenicol from ointments prepared with Eye ointment BP or Simple ointment BP base 
Time (h) ncentration of surfactant (%w/v) Base: Eye ointment BP Base: Simple ointment BP 
Surfactant/Mean percent drug released Surfactant/Mean percent drug releaseda a 
Propylene glycol Polysorbate 80 Propylene glycol Polysorbate 80 
  0 2.8 (1.1) b 2.8 (1.1) 4.1 (0.4) 4.1 (0.4) 
  0.1 5.7 (2.0) 0.7 (0.5) 0.9 (1.0) 8.5 (6.0) 
0.5 0.5 4.1 (2.0) 2.5 (5.1) 1.9 (2.0) 7.7 (5.0) 
  1 3.9 (1.1) 4.7 (2.0) 2.2 (2.3) 8.5 (2.0) 
  5 4.8 (0.8) 3.2 (2.0) 3.0 (1.5) 5.1 (1.5) 
  10 8.0 (1.0) 4.5 (2.0) 8.1 (1.0) 10.6 (1.0) 
  0 2.8 (1.1) b 2.8 (1.1) 6.8 (0.4) 6.8 (0.4) 
  0.1 5.7 (2.0) 0.8 (0.5) 2.2 (1.0) 11.2 (6.0) 
1.0 0.5 5.0 (2.0) 4.8 (5.1) 3.4 (2.0) 9.4 (5.0) 
  1 4.3 (1.1) 4.7 (2.0) 3.4 (2.3) 9.3 (2.0) 
  5 5.9 (0.8) 4.8 (2.0) 3.9 (1.5) 8.3 (1.5) 
  10 13.2 (1.0) 5.1 (2.0) 8.1 (1.0) 14.7 (1.0) 
  0 3.1 (1.1) b 3.1 (1.1) 7.5 (0.4) 7.5 (0.4) 
  0.1 5.7 (2.0) 0.8 (0.5) 2.8 (1.0) 13.9 (6.0) 
1.5 0.5 5.0 (2.0) 5.7 (5.1) 4.3 (2.0) 11.7 (5.0) 
  1 4.3 (1.1) 4.7 (2.0) 4.7 (2.3) 9.3 (2.0) 
  5 6.2 (0.8) 5.9 (2.0) 5.3 (1.5) 9.8 (1.5) 
  10 13.5 (1.0) 6.1 (2.0) 8.1 (1.0) 17.4 (1.0) 
  0 3.8 (1.1) b 3.8 (1.1) 7.3 (0.4) 7.3 (0.4) 
  0.1 5.7 (2.0) 0.9 (0.5) 3.0 (1.0) 15.1 (6.0) 
2.0 0.5 5.0 (2.0) 6.4 (5.1) 4.9 (2.0) 13.3 (5.0) 
  1 4.3 (1.1) 4.7 (2.0) 4.7 (2.3) 9.3 (2.0) 
  5 6.2 (0.8) 6.9 (2.0) 6.1 (1.5) 12.1 (1.5) 
  10 13.5 (1.0) 6.9 (2.0) 8.1 (1.0) 18.9 (1.0) 
  0 3.8 (1.1) b 3.8 (1.1) 7.3 (0.4) 7.3 (0.4) 
  0.1 5.7 (2.0) 0.9 (0.5) 3.9 (1.0) 15.5 (6.0) 
2.5 0.5 5.0 (2.0) 7.2 (5.1) 5.6 (2.0) 15.5 (5.0) 
  1 4.3 (1.1) 4.7 (2.0) 4.7 (2.3) 9.3 (2.0) 
  5 6.2 (0.8) 6.9 (2.0) 6.6 (1.5) 14.8 (1.5) 
  10 13.5 (1.0) 6.9 (2.0) 8.1 (1.0) 18.4 (1.0) 
  0 3.9 (1.1) b 3.9 (1.1) 7.4 (0.4) 7.4 (0.4) 
  0.1 5.7 (2.0) 0.9 (0.5) 4.0 (1.0) 15.8 (6.0) 
3.0 0.5 5.0 (2.0) 7.2 (5.1) 5.6 (2.0) 15.8 (5.0) 
  1 4.3 (1.1) 4.7 (2.0) 4.7 (2.3) 9.3 (2.0) 
  5 6.2 (0.8) 6.9 (2.0) 7.3 (1.5) 14.4 (1.5) 
  10 13.5 (1.0) 6.9 (2.0) 8.1 (1.0) 18.9 (1.0) 
Key:-aStandard error values in parenthesis, b
 
Acute ocular irritation results 
0 % surfactant preparations contained no surfactant 
All the test animals appeared healthy and were active. The triplicate 
animals eye testing produced no ocular irritation with propylene 
glycol (10 %) and 7 ointments (namely, four neat bases: EO, SO, HS, 
NS; and chloramphenicol ointment prepared in SO, HW, and NS). The 
other test items caused irritation to different measures: Two of 3 
animals treated with neat HW showed corneal opacity, observed 1 h 
after instillation, and partial conjunctiva swelling occurred in 1 of 
the 2 positive corneal opacity cases. One of 3 animals showed 
conjunctiva redness within 1 h of administering polysorbate 80 (10 
%), chloramphenicol in HS and chloramphenicol in EO ointments. 
The drug in EO ointment also produced mild swelling of the eye lid. 
However, in every case, all the irritation signs were absent at the 24 
h assessment. Apart from the eye irritation results noted above, 
there were no other signs of gross toxicity, adverse pharmacologic 
effects or abnormal behavior. Table 5 shows the individual total and 
group mean ocular irritation scores. The maximum mean total score 
of 0.67 was obtained for polysorbate 80 (10 %) solution and for 
chloramphenicol in HS ointment; the drug in EO gave MMTS of 1.33, 
while neat HW produced the highest score of 14.0. According to the 
Kay and Calandra classification system, all the test items proved 
practically non-irritant except neat HW that was classified as mildly 
irritant.
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Table 5: Individual total scores and group mean scores for ocular Irritation 
Test item/Rabbit ID/No; Sex (M/F) Time-interval of observation/Individual total score 
Polysorbate 80 solution (10 %w/v) 1 h 24 h 48 h 72 h 
0061; F 2 0 0 0 
0095; F 0 0 0 0 
0023; F 0 0 0 0 
Group Total 2 0 0 0 
Group Mean Score 0.67 0 0 0 
Chloramphenicol (1 %w/w) in Hydrous Sheabutter 1 h 24 h 48 h 72 h 
0161; F 0 0 0 0 
0158; M 2 0 0 0 
0164; F 0 0 0 0 
Group Total 2 0 0 0 
Group Mean Score 0.67 0 0 0 
Chloramphenicol (1 %w/w) in Eye ointment basis 1 h 24 h 48 h 72 h 
0141; F 4 0 0 0 
0088; F 0 0 0 0 
0133; M 0 0 0 0 
Group Total 4 0 0 0 
Group Mean Score 1.33 0 0 0 
Hydrous Wool Fat (neat) 1 h 24 h 48 h 72 h 
0067; M 0 0 0 0 
0052; F 20 0 0 0 
0033; M 22 0 0 0 
Group Total 42 0 0 0 
Group Mean Score 14 0 0 0 
 
DISCUSSION 
This study meets the need to conduct ocular tolerance testing of eye 
ointment basis BP in order to investigate and validate its general 
acceptance as the standard ophthalmic ointment vehicle. Erstwhile 
untested probability that selected dermal ointment vehicles may be 
suitable for ophthalmic drug delivery has also been elucidated. The 
corneal epithelium is more permeable to medicinal agents than skin 
epithelium [27]. The in vivo rabbit eye test approximates to human 
physiological and anatomical characteristics and response [28], 
hence it was appropriate for the study.  
The drug release mechanism of chloramphenicol from the bases was 
determined as Higuchi (diffusion-controlled) model. Similar earlier 
studies reported fluconazole to be released from water-soluble 
ointment bases following zero order kinetics [29] and metronidazole 
released from different ointment base types following the Higuchi 
kinetics [19]. The selective enhancement of release of 
chloramphenicol from the EO and SO formulations is not unusual. 
Earlier studies indicated that inclusion of surfactant in semisolid 
drug delivery vehicle may sometimes increase [30] or decrease the 
release of incorporated drug [31, 32]. Characteristics demonstrated 
by neat HW base in this study were unique and different from those 
of other bases namely, non-conformity of its drug release potential 
with the observed trends against WAC and temperature 
susceptibility, and its (mild) ocular irritancy potential.  
CONCLUSION 
Chloramphenicol eye ointment formulations in five different bases, 
with and without surfactant, investigated in this study were all well 
tolerated and non-irritant to the eye. One test item only (neat HW) 
gave an overall eye irritation score (MMTS) of mild irritancy. All the 
four neat bases investigated in parallel as alternatives to EO showed 
greater propensity for delivering the drug from ointment than EO, 
with NS and HS demonstrating the highest potentials for both the 
rate and extent of drug release. WAC and softening temperature of 
base apparently influenced its drug release propensity. Whereas the 
presence of polysorbate 80 in chloramphenicol-in-EO formulation 
did not appreciably improve the drug release from the base, 
propylene glycol (10 %w/v) in similar formulation caused more 
than three-fold enhancement of the drug release.  
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